不明原因肝病中外泌体的研究进展

摘要/Abstract

摘要： 外泌体是一种直径为30~150 nm的双磷脂膜囊泡,包含大量特定的细胞内容物,如miRNA、mRNA、lncRNA、DNA、蛋白质、脂质等,靶向作用于受体细胞,参与细胞间信息交流。外泌体可作为诊断和预后的生物学标志,用于监测和评价各种肝脏疾病的诊疗情况,在肝病的诊断、治疗及预后中具有重要价值。尿液中的外泌体被认为是非侵入性的分子生物标志物;血液中的外泌体被认为是微创分子生物标志物,有可能代替以往的肝穿刺活组织检查技术,用于不明原因肝病的早期检测和预后。此外,外泌体及其携带组分参与了肝细胞的修复、再生和迁移等生理过程,因此可能是不明原因肝病的潜在治疗手段和治疗靶点。本文主要对外泌体的基本特性及不明原因肝病中外泌体的作用进行简要概述,为临床诊断和治疗不明原因肝病提供理论依据。

关键词: 外泌体, 不明原因肝病, 生物标志物, 治疗靶点

汪增秀, 赵宏宇, 吴卫锋, 宋金云. 不明原因肝病中外泌体的研究进展[J]. 肝脏, 2023, 28(8): 1001-1004.

参考文献

[1] Abels ER, Breakefield XO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol, 2016, 36(3):301-312.
[2] Whitford W, Guterstam P. Exosome manufacturing status. Future Med Chem, 2019, 11(10):1225-1236.
[3] 杨永峰. 不明原因肝病诊断思路. 实用肝脏病杂志, 2018, 21(1): 1-3.
[4] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science, 2020, 367(6478):eaau6977.
[5] Chung IM, Rajakumar G, Venkidasamy B, et al. Exosomes: current use and future applications. Clin Chim Acta, 2020, 500:226-232.
[6] Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem, 2019, 88:487-514.
[7] Xu Z, Zeng S, Gong Z, et al. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer, 2020, 19(1):160.
[8] Guo M, Yin Z, Chen F, et al. Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer's disease. Alzheimers Res Ther, 2020, 12(1):109.
[9] Todd KV, Tripp RA. Exosome-mediated human norovirus infection. PLoS One, 2020, 15(8):e0237044.
[10] Shen Z, Huang W, Liu J, et al. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol, 2021, 12:749192.
[11] Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J, 2019, 7(9):1156-1163.
[12] Lotfy A, Elgamal A, Burdzinska A, et al. Stem cell therapies for autoimmune hepatitis. Stem Cell Res Ther, 2021, 12(1):386.
[13] Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair. Cells, 2019, 8(8):784.
[14] Lou G, Chen Z, Zheng M, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med, 2017, 49(6):e346.
[15] Chen L, Lu FB, Chen DZ, et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis. Mol Immunol, 2018, 93:38-46.
[16] Lu FB, Chen DZ, Chen L, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying microRNA-223-3p. Mol Cells, 2019, 42(12):906-918.
[17] Zhao J, Li Y, Jia R, et al. Mesenchymal stem cells-derived exosomes as dexamethasone delivery vehicles for autoimmune hepatitis therapy. Front Bioeng Biotechnol, 2021, 9:650376.
[18] Tsuneyama K, Baba H, Morimoto Y, et al. Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms. J Med Invest, 2017, 64(1.2):7-13.
[19] Sarcognato S, Sacchi D, Grillo F, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica, 2021, 113(3):170-184.
[20] Tomiyama T, Yang GX, Zhao M, et al. The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cell Mol Immunol, 2017, 14(3):276-284.
[21] Liu R, Li X, Zhu W, et al. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatology, 2019, 70(4):1317-1335.
[22] Chen W, Zhu J, Lin F, et al. Human placenta mesenchymal stem cell-derived exosomes delay H₂O₂-induced aging in mouse cholangioids. Stem Cell Res Ther, 2021, 12(1):201.
[23] Garcia-Cortes M, Robles-Diaz M, Stephens C, et al. Drug induced liver injury: an update. Arch Toxicol, 2020, 94(10):3381-3407.
[24] Holman NS, Mosedale M, Wolf KK, et al. Subtoxic alterations in hepatocyte-derived exosomes: an early step in drug-induced liver injury? Toxicol Sci, 2016, 151(2):365-375.
[25] Cho YE, Kim SH, Lee BH, et al. Circulating plasma and exosomal micrornas as indicators of drug-induced organ injury in rodent models. Biomol Ther (Seoul), 2017, 25(4):367-373.
[26] Zheng J, Yu L, Chen W, et al. Circulating exosomal microRNAs reveal the mechanism of Fructus Meliae Toosendan-induced liver injury in mice. Sci Rep, 2018, 8(1):2832.
[27] Royo F, Schlangen K, Palomo L, et al. Transcriptome of extracellular vesicles released by hepatocytes. PLoS One, 2013, 8(7):e68693.
[28] Yang X, Weng Z, Mendrick DL,et al. Circulating extracellular vesicles as a potential source of new biomarkers of drug-induced liver injury. Toxicol Lett, 2014, 225(3):401-406.
[29] Cho YE, Im EJ, Moon PG, et al. Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury. PLoS One, 2017, 12(2):e0172463.
[30] Zhao L, Wang Y, Zhang Y. The potential diagnostic and therapeutic applications of exosomes in drug-induced liver injury. Toxicol Lett, 2021, 337:68-77.
[31] Tan CY, Lai RC, Wong W, et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther, 2014, 5(3):76.
[32] Holman NS, Church RJ, Nautiyal M, et al. Hepatocyte-derived exosomes promote liver immune tolerance: possible implications for idiosyncratic drug-induced liver injury. Toxicol Sci, 2019, 170(2):499-508.
[33] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2019, 69(6):2672-2682.
[34] Wang W, Zhu N, Yan T, et al. The crosstalk: exosomes and lipid metabolism. Cell Commun Signal, 2020, 18(1):119.
[35] Li Y, Luan Y, Li J, et al. Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism. Hepatol Int, 2020, 14(6):1057-1074.
[36] Yan C, Tian X, Li J, et al. A high-fat diet attenuates AMPK α1 in adipocytes to induce exosome shedding and nonalcoholic fatty liver development in vivo. Diabetes, 2021, 70(2):577-588.
[37] Liu XL, Pan Q, Cao HX, et al. Lipotoxic hepatocyte-derived exosomal microRNA 192-5p activates macrophages through Rictor/Akt/Forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease. Hepatology, 2020 , 72(2):454-469.
[38] Zhao Z, Zhong L, Li P, et al. Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p. Exp Cell Res, 2020, 387(1):111738.
[39] Gu H, Yang K, Shen Z, et al. ER stress-induced adipocytes secrete-aldo-keto reductase 1b7-containing exosomes that cause nonalcoholic steatohepatitis in mice. Free Radic Biol Med, 2021, 163:220-233.
[40] Hou X, Yin S, Ren R, et al. Myeloid-cell-specific IL-6 signaling promotes microRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis. Hepatology, 2021, 74(1):116-132.